AstraZeneca, Absci sign $247M agreement to uncover AI-driven cancer drug candidates

The companies will leverage Absci ' s AI-enabled Integrated Drug Creation platform and the pharma giant ' s oncology research and development expertise.
Source: mobihealthnews - Category: Information Technology Source Type: news